Humacyte Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
44.1%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.35next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Symvess Commercial Sales Quarterly500KTarget: Expansion to over 200 hospitals
V012 Phase 3 Primary Endpoint (Catheter-Free Days) Annually220.0Target: 129 (AV fistula control benchmark)
Cash, Cash Equivalents, and Restricted Cash Quarterly48.9MTarget: Sufficient runway to support commercial launch and pipeline milestones
Watch Items
- Supplemental BLA (sBLA) submission for hemodialysis AV access indicationTrigger: Submission window planned for second half of 2026Action: Compile and submit combined clinical data from V012 and V007 Phase 3 pivotal studies to the FDA
- First-in-human Phase I/II clinical trial of Coronary Tissue Engineered Vessel (CTEV) in CABGTrigger: Commencement planned for second half of 2026Action: Obtain FDA clearance of the Investigational New Drug (IND) application and initiate patient enrollment
- Workforce restructuring and cost-reduction program executionTrigger: Targeted net savings of approximately $14.3 million during the remainder of 2026Action: Monitor operating expense run-rate and manage the one-time restructuring charge of $0.8 million
Research as of 20 Jun 2026